Related Experiment Video
Updated: Mar 23, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in
A Hilario1, J M Sepulveda2, A Hernandez-Lain3
1Department of Radiology, Hospital 12 de Octubre, Avenida de Cordoba s/n, 28041, Madrid, Spain. amayahilario@yahoo.es.
Summary
Tumor leakage reduction on MRI scans after bevacizumab treatment can predict survival in recurrent glioblastoma patients. This decrease in vascular permeability may serve as a biomarker for treatment effectiveness.
Area of Science:
- Neuro-oncology
- Radiology
- Pharmacology
Background:
- Glioblastoma progression is linked to vascular endothelial growth factor (VEGF).
- Bevacizumab, an anti-VEGF antibody, inhibits angiogenesis but treatment response doesn't always correlate with tumor changes.
- Dynamic susceptibility contrast (DSC) perfusion MRI measures blood vessel leakage.
Purpose of the Study:
- To determine if DSC perfusion MRI-derived leakage changes predict survival in recurrent glioblastoma.
- To assess if baseline leakage relates to treatment outcomes in patients receiving bevacizumab.
Main Methods:
- Retrospective analysis of DSC perfusion MRI in 24 recurrent glioblastoma patients treated with bevacizumab.
- Quantitative analysis of baseline and follow-up leakage.
- Kaplan-Meier survival analysis and log-rank tests.
Main Results:
- Reduced leakage at 8 weeks post-treatment significantly influenced overall survival (OS) and progression-free survival (PFS).
- Patients with leakage reduction experienced longer median OS (2.4 months) and PFS (2.8 months).
- Higher baseline leakage correlated with post-treatment leakage reduction and predicted treatment response (Odds Ratio=9 for leakage >5].
Conclusions:
- Decreased tumor leakage is a potential predictor of OS and PFS in bevacizumab-treated recurrent glioblastomas.
- Leakage reduction may serve as a biomarker for evaluating treatment response.
- Baseline leakage appears to predict treatment response but not independently survival.
